Johnson & Johnson down 1.4% afterhours following punitive damage award report

A jury award that hit Johnson & Johnson with $8 billion in punitive damages for a case involving its anti-psychotic drug Risperdal highlights the risks of the drugmaker's all-or-nothing legal strategy, several legal experts told Reuters on Wednesday......»»

Shares of Johnson & Johnson dipped 1% Wednesday after a jury awarded $8 billion in punitive damages to a man who accused the drugmaker of failing to warn that young men using its antipsychotic drug Risperdal could grow breasts......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Johnson & Johnson must pay $4.14 billion in punitive damages to women who claimed asbestos in the company’s talc products caused them to develop ovarian cancer. The company’s shares dropped in afterhours trading......»»

Johnson & Johnson must pay $4.14 billion in punitive damages to women who claimed asbestos in the company’s talc products caused them to develop ovarian cancer. The company’s shares dropped in afterhours trading......»»

Johnson & Johnson (NYSE: JNJ) is set to release earnings results for its first quarter before the opening bell on April 16, 2024. Latest Ratings for J.....»»

Johnson & Johnson's Q1 earnings report on April 16 is expected to show $2.64 EPS and $21.4 billion in revenues. Technical analysis shows a bearish trend but analysts have a neutral rating with a $171.95 price target and potential 37.15% upside. read more.....»»

Johnson's comments come as investors brace for the latest Consumer Price Index (CPI) report. read more.....»»

Debt claims like the one issued against Boris Johnson by political opponents to damage .....»»

Released Wednesday, the new documents shed l.....»»

J&J privately contacted rival drugmakers also producing COVID-19 vaccines to join the study, and only AstraZeneca agreed, WSJ reports. Johnson & Johnson privately contacted other drugmakers producing COVID-19 vaccine to join a study into the p.....»»

The S&P 500 finished at a record and technol.....»»

S.C. Johnson & Son Inc. possesses a strong brand portfolio, global reach and pricing power that bode well for continuing payments on $3 billion in long-term debt while seeking more acquisitions, according to a new report from Fitch Ratings. Fi.....»»

President Joe Biden on Wednesday afternoon will announce plans to secure an additional 100 million doses of Johnson & Johnson's COVID-1.....»»

Oatly recorded $200 million in sales in 2019, and expected to double that figure to $400 million in 2020 and become profitable by 2021, a report said. Hollis Johnson/INSIDER Oatly, the popular alternative milk company that's backed by Opra.....»»

Boris Johnson discussed a new variant of coronavirus with ministers in an emergency meeting. A London travel ban was report.....»»

As many as 43 million Americans could lose their health insurance in the midst of the coronavirus pandemic, according to a new report from the Robert Wood Johnson Foundation and the Urban Institu.....»»

Germany's Top Soccer League To Restart Play In 2 Weeks: Live Updates Summary: Boris Johnson to unveil plan to end UK lockdown on Sunday Scotland says 60% of recent COVID-19 deaths linked to nursing homes China report.....»»

Firms' largest sales of 2020 1st quarterCheck out Ken Fisher Stock Picks » Download GuruFolio Report of Ken Fisher (Updated on 04/28/2020)Related Stocks: PFE, JNJ, SFTBY, UBS, HSBC, PG,.....»»

A trial in a New York hospital is testing the heartburn medication Pepcid as a treatment for COVID-19, according to a report in Science. Pepcid, a generic drug marketed by Merck and Johnson & Johnson .....»»